Successfully Treating Kaposi Sarcoma: Robert Yarchoan, MD
Sarah Williams, MAT
Expert Analysis
Robert Yarchoan, MD, Chief of the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI), recently spoke with i3 Health about the approval of pomalidomide (Pomalyst®, Celgene) for Kaposi sarcoma in patients with and without HIV. In this second installment of his interview, Dr. Yarchoan shares valuable advice with oncologists as they ...
Burosumab-twza for Tumor-Induced Osteomalacia: Suzanne Jan de Beur, MD
Keira Smith
Expert Analysis
In this interview with i3 Health, Suzanne Jan de Beur, MD, discusses the recent approval of burosumab-twza (Crysvita®, Ultragenyx Pharmaceutical, Inc.), for patients with tumor-induced osteomalacia (TIO) whose tumors are unable to be localized or resected. Dr. Jan de Beur, lead investigator of one of the phase 2 clinical trials on which the approva...
Gemtuzumab Ozogamicin for Pediatric Acute Myeloid Leukemia: Alan S. Gamis, MD, MPH
Keira Smith
Expert Analysis
In this interview, Alan S. Gamis, MD, MPH, speaks with i3 Health about the recent FDA approval of gemtuzumab ozogamicin (MylotargTM, Wyeth Pharmaceuticals, LLC) for pediatric patients aged 1 month and older with newly diagnosed CD33-positive acute myeloid leukemia (AML). Dr. Gamis, lead investigator of the phase 3 Children's Oncology Group Trial AA...
Treatment Advances in Gastrointestinal Stromal Tumor: Margaret von Mehren, MD
Sarah Williams, MAT
Expert Analysis
The treatment of gastrointestinal stromal tumor (GIST), a rare tumor type with an estimated incidence of 3,300 to 6,000 new cases per year in the United States, has seen exciting advances this year, first with the FDA's approval of avapritinib for metastatic GIST with platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations, and mor...
Ken Kato, MD, PhD: FDA Approval of Nivolumab for Esophageal Squamous Cell Carcinoma
Emily Levitch
Expert Analysis
The FDA recently approved nivolumab for patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who have received prior fluoropyrimidine- and platinum-based chemotherapy. Ken Kato, MD, PhD, lead author on the study the approval was based on, spoke to i3 Health about the challenges of treating this pat...
Metronomic Capecitabine Maintenance for TNBC: Zhongyu Yuan, MD
Emily Levitch
Expert Analysis
Metronomic capecitabine maintenance therapy has been shown to be more effective compared with observation for patients with triple-negative breast cancer (TNBC), according to a study led by Zhongyu Yuan, MD. Results of the study have been presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. In this intervie...
Rucaparib for BRCA-Mutated Castration-Resistant Prostate Cancer: Nicholas Vogelzang, MD
Keira Smith
Expert Analysis
In this interview, Nicholas Vogelzang, MD, speaks with i3 Health about the recent FDA approval of rucaparib (Rubraca®, Clovis Oncology, Inc.) for the treatment of patients with metastatic BRCA-mutated castration-resistant prostate cancer (CRPC) who previously received one line of taxane-based chemotherapy and at least one line of androgen receptor-...
Pomalidomide for Kaposi Sarcoma: Robert Yarchoan, MD
Sarah Williams, MAT
Expert Analysis
The FDA's recent accelerated approval of pomalidomide (Pomalyst®, Celgene) for Kaposi sarcoma in patients with and without HIV marked the first approval for this cancer in over 20 years. In this interview with i3 Health, Robert Yarchoan, MD, Chief of the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI) and principal investigato...
Olaparib for BRCA-Mutated Ovarian Cancer: Andrés Poveda, MD
Keira Smith
Expert Analysis
Last weekend, in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, Andrés Poveda, MD, presented results of the phase 3 SOLO2/ENGOT Ov-21 trial, reporting that olaparib significantly increased median overall survival compared with placebo in patients with platinum-sensitive BRCA-mutated relapsed ovarian cancer. In thi...
Ripretinib for Advanced Gastrointestinal Stromal Tumor: Margaret von Mehren, MD
Sarah Williams, MAT
Expert Analysis
Ripretinib (QinlockTM, Diciphera Pharmaceuticals, LLC) represents a new option for patients with advanced gastrointestinal stromal tumor (GIST) previously treated with at least three kinase inhibitors, including imatinib. In this interview with i3 Health, Margaret von Mehren, MD, lead investigator of the INVICTUS study, on which ripretinib's recent...
Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma: John Kuruvilla, MD
Keira Smith
Expert Analysis
This past weekend in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, John Kuruvilla, MD, presented results of the phase 3 KEYNOTE-204 trial, reporting that pembrolizumab significantly increased progression-free survival compared with brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma....
Selinexor/Bortezomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: Meletios Dimopoulos, MD
Keira Smith
Expert Analysis
In the phase 3 BOSTON trial, a team of researchers led by Meletios Dimopoulos, MD, found that selinexor/bortezomib/dexamethasone (SVd) significantly improved survival compared with bortezomib/dexamethasone (Vd) alone in patients with multiple myeloma who had received one to three prior lines of therapy. The trial's results were recently presented i...
Atezolizumab for PD-L1–High Non-Small Cell Lung Cancer: David Spigel, MD
Keira Smith
Expert Analysis
Atezolizumab (Tecentriq®, Genentech, Inc.) was recently approved by the FDA for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with high expression of programmed death ligand-1 (PD-L1). The approval was based on IMpower110, a phase 3 trial led by David Spigel, MD, Chief Scientific Officer and Director of the...
Selpercatinib for RET-Altered Thyroid Cancer and MTC: Lori Wirth, MD
Keira Smith
Expert Analysis
In this interview, Lori Wirth, MD, speaks with i3 Health about selpercatinib (RetevmoTM, Eli Lilly), which was recently approved by the FDA for the treatment of patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced/metastatic RET-mutant medullary thyroid cancer (MTC), and advanced/metastatic RET fusion-positive t...
Exciting Treatment Advances in Upper Tract Urothelial Cancer: Seth P. Lerner, MD, FACS
Sarah Williams, MAT
Expert Analysis
Substantial developments are under way in the treatment of upper tract urothelial cancer (UTUC). Seth P. Lerner, MD, FACS, recently spoke with i3 Health about mitomycin gel (JelmytoTM, UroGen Pharma), now FDA approved as the first agent specifically indicated for the treatment of low-grade UTUC. In this second installment of his interview, Dr. Lern...
Tucatinib for HER2-Positive Metastatic Breast Cancer: Eric P. Winer, MD
Sarah Williams, MAT
Expert Analysis
In this interview with i3 Health, Eric P. Winer, MD, discusses tucatinib (TukysaTM, Seattle Genetics), recently approved by the FDA in combination with trastuzumab and capecitabine for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least one anti-HER2­–based...
​COVID-19 and Cancer: Addressing Patients' Concerns With Mark A. Lewis, MD
Sarah Williams, MAT
Expert Analysis
Patients with cancer often have concerns related to the COVID-19 pandemic, from which they are potentially at increased danger as a result of their cancer and/or due to immunosuppressive treatments. Mark A. Lewis, MD, Director of Gastrointestinal Oncology at Intermountain Healthcare, Murray, Utah, recently published a perspective piece in The New E...
Family History-Based Colorectal Cancer Screening: Samir Gupta, MD
Keira Smith
Expert Analysis
Colorectal cancer rates in younger adults are currently rising, and those with a family history of the disease face an even greater risk. Samir Gupta, MD, Chief of the Gastrointestinal (GI) Section of the San Diego Veterans Affairs Healthcare System, recently spoke with i3 Health about his research team's finding, now published in Cancer, that only...
COVID-19 Outcomes in Patients With Cancer: Miao Liu, MD, PhD
Keira Smith
Expert Analysis
Patients with cancer face unique challenges in the midst of the COVID-19 pandemic: not only do they have an increased risk of contracting COVID-19 in hospital settings, but they also experience more severe clinical outcomes from the disease compared with patients without cancer. In this interview with i3 Health, Miao Liu, MD, PhD, one of the invest...
Sacituzumab Govitecan for TNBC: An Interview With Sara Tolaney, MD, MPH
Emily Levitch
Expert Analysis
The FDA recently granted approval to sacituzumab govitecan-hziy (Trodelvy™, Immunomedics, Inc) for patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies. Approval was based on a clinical trial (NCT01631552) that enrolled 108 patients with metastatic TNBC. In an interview with i3 Health, Sara To...

Copyright © 2022 Oncology Data Advisor. All rights reserved.